Secuado vs. Aristada

Secuado (asenapine) and Aristada (aripiprazole lauroxil) are atypical antipsychotics used to treat adults with schizophrenia.

Secuado is available as a transdermal system (patch) and Aristada is an intramuscular injection.

Asenapine, the drug contained in Secuado, is also available as a sublingual tablet formulation under the brand name Saphris.

Side effects of Secuado and Aristada that are similar include headache and weight gain.

Side effects of Secuado that are different from Aristada include extrapyramidal disorder (muscle spasms, restlessness, muscle rigidity, slowness of movement, tremors, and irregular, jerky movements) and application site reactions (skin discoloration, discomfort, dryness, swelling, redness, peeling, hard lump, irritation, pain, bumps, or itching).

Side effects of Aristada that are different from Secuado include feeling the urge to move constantly (akathisia), injection site reactions (pain, swelling, redness, a hard lump), insomnia, restlessness, and increased blood creatine phosphokinase (CPK).

Both Secuado and Aristada may interact with antihypertensive drugs.

Secuado may also interact with diuretics, fluvoxamine, ciprofloxacin, enoxacin, and paroxetine.

Aristada may also interact with oral aripiprazole, carbamazepine, and benzodiazepines.

Side effects of Secuado include:

• headache,
• extrapyramidal disorder (muscle spasms, restlessness, muscle rigidity, slowness of movement, tremors, and irregular, jerky movements),
• application site reactions (skin discoloration, discomfort, dryness, swelling, redness, peeling, hard lump, irritation, pain, bumps, or itching), and
• weight gain

Common side effects of Aristada include:

• feeling the urge to move constantly (akathisia),
• injection site reactions (pain, swelling, redness, a hard lump),
• weight gain,
• headache,
• insomnia,
• restlessness, or
• increased blood creatine phosphokinase (CPK).

Secuado (asenapine) is a transdermal atypical antipsychotic formulation used to treat adults with schizophrenia. Asenapine, the drug contained in Secuado, is also available as a sublingual tablet formulation under the brand name Saphris.

Secuado is also used to treat or manage:

• Schizophrenia
• manic or mixed episodes that happen with bipolar I disorder
• major depressive disorder (MDD) when ABILIFY is used with antidepressant medicines
• irritability associated with autistic disorder
• Tourette's disorder

Secuado Injection is a prescription medicine used to treat:

• agitation associated with schizophrenia or bipolar mania

It is not known if Secuado is safe or effective in children:

• under 13 years of age with schizophrenia
• under 10 years of age with bipolar I disorder
• under 6 years of age with irritability associated with autistic disorder
• under 6 years of age with Tourette's disorder

Aristada (aripiprazole lauroxil) is an atypical antipsychotic indicated for the treatment of schizophrenia.

Secuado may interact with other medicines such as:

• diuretics,
• ACE inhibitors,
• angiotensin receptor blockers (ARBs),
• beta-blockers,
• alpha-blockers,
• fluvoxamine,
• ciprofloxacin,
• enoxacin, and
• paroxetine

Tell your doctor all medications and supplements you use.

Aristada may interact with oral aripiprazole, carbamazepine, antihypertensive drugs, and benzodiazepines. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before taking Aristada. Aristada may cause extrapyramidal and/or withdrawal symptoms in neonates in women exposed during the third trimester of pregnancy. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Aristada during pregnancy. Aristada passes into breast milk but its effects on a nursing infant are unknown. Consult your doctor before breastfeeding.

The recommended starting dose of Secuado is 3.8 mg/24 hours. Apply one Secuado patch to the skin (hip, abdomen, upper arm, or upper back area) every 24 hours

Aristada is administered by intramuscular injection in the deltoid (441 mg dose only) or gluteal (441 mg, 662 mg or 882 mg) muscle by a healthcare professional.